Saudi Vigilance Program: Challenges and lessons learned
| Autor: | Mubarak Alshahrani, Ali Alshahrani, Nasser Alqahtani, Saleh A. Bawazir, Ghazi Saeed, Mohammed Alquwaizani, Adel A. Alharf, Nasser Aljasser |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Pharmacology
medicine.medical_specialty Medical education media_common.quotation_subject Public health lcsh:RM1-950 education Pharmaceutical Science 030226 pharmacology & pharmacy Article Pharmacovigilance 03 medical and health sciences lcsh:Therapeutics. Pharmacology 0302 clinical medicine Spontaneous reporting medicine Saudi Vigilance Program Saudi Food and Drug Authority 030212 general & internal medicine Business Early phase Healthcare providers Vigilance (psychology) media_common |
| Zdroj: | Saudi Pharmaceutical Journal, Vol 26, Iss 3, Pp 388-395 (2018) |
| Popis: | Pharmacovigilance is vital to public health. Adopting a robust spontaneous reporting system for adverse drug events can counteract most hazards that arise from utilizing medicinal products. Prior to the establishment of the Saudi Food and Drug Authority (SFDA), the number of pharmacovigilance-related activities in Saudi Arabia was limited. In 2009, the SFDA established the National Pharmacovigilance and Drug Safety Center (Saudi Vigilance). The pharmacovigilance system has remarkably improved during the past few years. Several initiatives have been taken to improve the program’s performance. These initiatives include initiation of pharmacovigilance guidelines, enhancement of communication and reporting tools, training sessions for concerned staff and healthcare providers, and compliance from stakeholders. This review article provides an overview of what the Saudi Vigilance program is, focusing on the scope, mission and vision, hierarchy, operational themes, and overall work processes. Additionally, we will shed light on the challenges we encountered during the early phase and on our future plans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|